The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided promising results about it. The aim of this study was to evaluate if therapy with omalizumab in patients affected by asthma and allergic rhinitis has an impact also on allergic rhinitis-related symptoms.
Effects of omalizumab therapy on allergic rhinitis: a pilot study / MASIERI, Simonetta; CAVALIERE, CARLO; Begvarfaj, E; ROSATI, DAVIDE; MINNI, Antonio. - In: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES. - ISSN 1128-3602. - STAMPA. - 20:24(2016), pp. 5249-5255.
Effects of omalizumab therapy on allergic rhinitis: a pilot study
MASIERI, SimonettaPrimo
;CAVALIERE, CARLOSecondo
;Begvarfaj, E;ROSATI, DAVIDEPenultimo
;MINNI, Antonio
Ultimo
2016
Abstract
The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided promising results about it. The aim of this study was to evaluate if therapy with omalizumab in patients affected by asthma and allergic rhinitis has an impact also on allergic rhinitis-related symptoms.| File | Dimensione | Formato | |
|---|---|---|---|
|
Masieri_Effects omalizumab therapy_2016.pdf
accesso aperto
Note: https://www.europeanreview.org/article/11940
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
772.68 kB
Formato
Adobe PDF
|
772.68 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
